Promise and pitfalls of quantitative imaging in oncology clinical trials

Abstract

Quantitative imaging using CT, MRI, and PET modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network (QIN) addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size, but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor, and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer, and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs, and institutional barriers. Strategies for overcoming these constraints are presented.

Quantitative Imaging in Cancer Evolution and Ecology

“…Such models use links between observable tumor characteristics and microenvironmental selection factors to make testable predictions about emergent phenotypes. One such theoretical framework is the in an effort to understand their clinical and biologic implications (1,2). In parallel, technical advances now permit extensive molecular characterization of tumor cells in individual patients.…”

Prediction of clinical phenotypes in invasive breast carcinomas from the integration of radiomics and genomics data

“…3,4 Genomic profiling of tumor is usually obtained through invasive procedures, such as biopsy and surgery, providing direct observation on the molecular underpinnings of the tumor. The integration of these two different data modalities provides opportunities to investigate whether combining radiomics and genomics can achieve better prediction of tumor clinical types than using either alone.…”

Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom

“…These results should make it possible to identify and recommend make-and-model-specific reconstruction strategies to minimize measurement variability in cancer clinical trials. Mul ticenter oncology clinical trials are increasingly using PET/CT imaging as primary and secondary endpoints to define success or failure of treatment regimens, with considerable effort expended in understanding reproducibility and variability (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). PET, as an inherently quantitative imaging technique, is arguably the most powerful imaging modality available to researchers to assess response to therapy in the multicenter clinical trial setting.…”